# The Present and Future of Zone 0 Endovascular Arch Reconstruction

**Authors:** Ming Hao Guo, Robert-James Doonan, Mark Rockley

PMC · DOI: 10.3390/jcdd13020093 · Journal of Cardiovascular Development and Disease · 2026-02-13

## TL;DR

Endovascular techniques for treating aortic arch issues are being developed as safer alternatives to open surgery, but challenges like stroke risk and inconsistent data remain.

## Contribution

The paper highlights the need for standardized data collection and high-quality studies to improve outcomes in zone 0 arch reconstruction.

## Key findings

- Endovascular approaches have high stroke rates and lack long-term outcome data.
- Small sample sizes and inconsistent techniques hinder progress in this field.
- Multicenter trials or registries with standardized protocols are needed for better insights.

## Abstract

Thoracic aortic pathology involving the aortic arch is most commonly treated with open total arch replacement. However, open surgery is still associated with significant risk of mortality and morbidity, particularly in the elderly, patients with high-risk comorbidities, and those with previous cardiac surgery. Multiple endovascular approaches to enable zone 0 arch reconstruction have been developed, including custom-made, physician-modified, and off-the-shelf fenestrated/branched endografts. The initial experiences of this approach have been plagued by high incidence of stroke; although improvements have been made over the past decade, it remains suboptimal. Several factors contribute to this stagnation, including limited descriptive studies with small sample sizes, heterogeneous patient populations, varied techniques, and lack of data granularity and standardization. These limitations reduce the ability to analyze factors that could improve patient selection, device design, and procedural techniques. In addition, consistent follow-ups have not been reported, and the long-term outcome of these interventions are unknown. To address these issues, a randomized controlled trial of open versus endovascular arch repair or multicenter registry with standardized data reporting, follow-up protocol, and sufficient sample size would be needed. High-quality data will help identify patient clinical or anatomical features as well as procedural factors that can improve outcomes.

## Full-text entities

- **Diseases:** paraplegia (MESH:D010264), upper limb ischemia (MESH:D007511), neurological deficit (MESH:D009461), Stroke (MESH:D020521), Marfan syndrome (MESH:D008382), A dissection (MESH:D000784), pseudoaneurysm (MESH:D017541), ischemic (MESH:D002545), aneurysm (MESH:D000783), Endoleak (MESH:D057867), blood loss (MESH:D016063), aortic disease (MESH:D001018), myocardial fibrosis (MESH:D005355), cerebral hypoperfusion (MESH:D002547), hematoma (MESH:D006406), degenerative aneurysm (MESH:D019636), injury to (MESH:D014947), fracture (MESH:D050723), atheroma (MESH:D058226), paraparesis (MESH:D020335), 1a (MESH:C536041), embolic (MESH:D004617), myocardial dysfunction (MESH:D006331), postoperative (MESH:D019106), TEVAR (MESH:D049914), ulcer (MESH:D014456), CMD (MESH:C565145), gutter leak (MESH:D019559), cerebrovascular (MESH:D002561), thrombus (MESH:D013927), hypothermia (MESH:D007035), anemia (MESH:D000740), Aortic stiffness (MESH:C566100), haemorrhagic stroke (MESH:D002543), atherosclerosis (MESH:D050197), left ventricular hypertrophy (MESH:D017379), died (MESH:D003643)
- **Chemicals:** polytetrafluoroethylene (MESH:D011138), CO2 (MESH:D002245), antiplatelet (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941005/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12941005/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941005/full.md

---
Source: https://tomesphere.com/paper/PMC12941005